DIAGNOS announces the roll-out of its age-related macular solution

BROSSARD, Quebec, June 07, 2022 (GLOBE NEWSWIRE) — DIAGNOS Inc. (“DIAGNOSTIC“, the “societyor “we”) (TSX Venture: ADK) (OTCQB: DGNOF) a leader in the early detection of critical health conditions through the use of its FLAIRE Platform based on Artificial Intelligence (AI), is pleased to announce the deployment of its age-related macular degeneration detection application in the optometry clinics of IRIS Le Groupe Visuel.

It is with great pleasure that DIAGNOS announces the deployment of its Age-Related Macular Degeneration (AMD) detection application in the optometry clinics of IRIS The Visual Group (IRIS). With over 1,250 patients having already received this new test, we can see that there is strong demand for this application in clinical optometry and optical retail. This deployment of this application represents an important step in the artificial intelligence technology implementation program announced in June 2021 by the two groups.

“We are excited about the addition of the AMD detection application to our portfolio, as it further expands the value our company provides to eye care providers, an important segment of our market expansion strategy.” said Mr. Yves-Stéphane Couture, vice-president of DIAGNOS. “The quality of the relationship that we have developed with IRIS throughout this project and the constant spirit of collaboration and desire to improve patient outcomes shared by our respective organizations have been decisive in the development of this new tool, it contributed positively and directly to the deployment that we are doing today.

AMD is one of the main causes of visual deterioration and legal blindness in people over the age of 60. Loss of central vision and high-resolution visual acuity due to untreated AMD can lead to irreversible reading loss, depression, reduced facial recognition ability, and disqualification from driving. Regular screening for eye diseases is of the utmost importance to enable early detection of eye diseases and prevent major alterations in quality of life.

“The deployment of this new application in our clinics is perfectly in line with IRIS’ desire to be at the forefront of technological advances in its clinical optometry and optical retail operations. We strive to provide our customers with the most effective cutting-edge technologies, with tools that enhance the healthcare experience we provide and improve clinical outcomes. Artificial Intelligence solutions like that of DIAGNOS raise the bar in terms of quality of care and perfectly illustrate the benefits of our collaboration with this company. said Dr. Jahel St-Jacques, optometrist and vice-president of IRIS.

DIAGNOS is currently putting the finishing touches on several artificial intelligence deep learning algorithms focused on disease detection and aimed at improving clinical operations and patient outcomes. The launch of AMD’s detection application is the first in a series of important launches planned soon, which will ensure the success and sustainability of the organization.

About IRIS
IRIS was founded in 1990 in Quebec. Since that time, IRIS has become the largest network of optometrists, opticians and ophthalmologists operating under the same banner across Canada. The Company’s locations combine clinical optometry and optical retail to provide a unique concept and commitment to providing superior eye care products and services.

Additional information is available at www.iris.ca

DIAGNOS is a publicly traded Canadian company dedicated to the early detection of critical health conditions based on its artificial intelligence (AI) platform FLAIRE. FLAIRE makes it possible to quickly modify and develop applications such as CARA (Computer Assisted Retina Analysis). CARA’s image enhancement algorithms provide sharper, clearer and easier to analyze retinal images. CARA is a cost-effective tool for real-time screening of large patient volumes. CARA has been cleared for marketing by the following regulatory agencies: Health Canada, FDA (USA), CE (Europe), COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia).

Additional information is available at www.DIAGNOS.com and www.sedar.com

This press release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this press release is expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Comments are closed.